April 2023 in “Research Society and Development” Corticosteroids are safe and effective for treating Alopecia Areata.
May 2024 in “Journal of Education, Health and Sport” Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
3 citations
,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
170 citations
,
September 2020 in “Viruses” Drug repositioning offers a cost-effective, lower-risk way to treat diseases and pandemics like COVID-19.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
October 2021 in “International Journal of Dermatology” JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” Topical corticosteroids are the best initial treatment for children's alopecia areata.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
12 citations
,
March 2023 in “Frontiers in immunology” Atopic dermatitis increases the risk of some autoimmune diseases.
1 citations
,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
October 2025 in “Journal of Advanced Trends in Medical Research” Rosemary shows promise in treating alopecia, similar to minoxidil, but more research is needed.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.